Venetoclax induces deep and durable minimal residual disease-negative remission in high-risk TP53 disrupted B prolymphocytic leukaemia.

Abstract

B-cell prolymphocytic leukaemia (B-PLL) is an aggressive B-cell lymphoproliferative disease with few clinically proven targeted treatments. Due to the rarity of the condition, there is a paucity of clinical trial data and none that involve targeted inhibitors. We present a unique case of relapsed refractory B-PLL treated to a sustained minimal residual disease-negative remission with venetoclax monotherapy, to add to the current evidence base and rationale for future studies using BCL-2 inhibitors in B-PLL.

• Authors: Lucia Y Chen, Toby A Eyre
• Journal: European journal of haematology (Eur J Haematol) Vol. 109 Issue 5 Pg. 590-592 (Nov 2022) ISSN: 1600-0609 [Electronic] England
• PMID: 35871485 (Publication Type: Case Reports)
• Copyright: © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Bridged Bicyclo Compounds, Heterocyclic
• Proto-Oncogene Proteins c-bcl-2
• Sulfonamides
• TP53 protein, human
• Tumor Suppressor Protein p53
• venetoclax

Topics

• Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)
• Humans
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)
• Leukemia, Prolymphocytic, B-Cell (diagnosis, drug therapy, etiology)
• Neoplasm, Residual
• Proto-Oncogene Proteins c-bcl-2 (genetics)
• Sulfonamides
• Tumor Suppressor Protein p53